Variable name;level;Overall;Yes;No;p;test
;n;1357;23;225;;
Age;[0 -30);95;2 (3.3);58 (96.7);0.003;
;[30 -35);246;8 (7.2);103 (92.8);;
;[35 -40);460;11 (15.1);62 (84.9);;
;40+;554;2 (50);2 (50);;
Number of children;0;373;20 (11.8);149 (88.2);0.126;
;1;279;2 (4.1);47 (95.9);;
;More than 1;705;1 (3.3);29 (96.7);;
BMI;<18.5;79;1 (6.7);14 (93.3);0.906;
;25-29.9;257;3 (6.8);41 (93.2);;
;>=30;107;1 (8.3);11 (91.7);;
;18.5-24.9;807;17 (10);153 (90);;
Treatment center;Curie Paris;818;16 (10.1);143 (89.9);0.731;
;Curie St Cloud;538;7 (7.9);82 (92.1);;
Hereditary predisposition;No;547;14 (9.3);136 (90.7);0.893;
;Yes;140;3 (7.1);39 (92.9);;
Inflammatory BC;No;1338;23 (9.3);223 (90.7);1.000;
;Yes;18;0 (0);2 (100);;
Clinical Tumor size (mm);;30.3 (21.7);31.7 (23.4);31.5 (19.4);0.951;
Clinical N stage (TNM);N0;854;16 (10.3);139 (89.7);NaN;
;N1;482;6 (6.5);86 (93.5);;
;N2;7;0 (NaN);0 (NaN);;
;N3;3;0 (NaN);0 (NaN);;
SBR grade;Grade I;58;1 (9.1);10 (90.9);0.450;
;Grade II;528;6 (6.4);88 (93.6);;
;Grade III;760;16 (11.3);126 (88.7);;
Histological type;Lobular;54;0 (0);6 (100);0.496;
;NST;1265;23 (9.8);212 (90.2);;
;Others;36;0 (0);7 (100);;
Neoajuvant chemotherapy;No;744;12 (10.5);102 (89.5);0.684;
;Yes;612;11 (8.2);123 (91.8);;
Chemotherapy setting;Adjuvant;744;12 (10.5);102 (89.5);NaN;
;Chemotherapy without surgery;1;0 (NaN);0 (NaN);;
;NAC;611;11 (8.2);123 (91.8);;
Fertility preservation discussion;No;909;0 (0);3 (100);1.000;
;Yes;447;23 (9.4);222 (90.6);;
